[HTML][HTML] Methylation modification of non-histone proteins in breast cancer: An emerging targeted therapeutic strategy
M Huang, Z Jiang, Y Xu, C Wu, W Ding, X Meng… - Pharmacological …, 2024 - Elsevier
Breast cancer is a major public health concern worldwide, being the most commonly
diagnosed cancer among women and a leading cause of cancer-related deaths. Recent …
diagnosed cancer among women and a leading cause of cancer-related deaths. Recent …
Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy
Simple Summary Addressing RB1-deficient cancers poses substantial challenges.
Dysfunctional or deleted RB1 can enhance the proliferation and spread of different cancer …
Dysfunctional or deleted RB1 can enhance the proliferation and spread of different cancer …
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma
L Dong, C Liu, H Sun, M Wang, M Sun, J Zheng, X Yu… - Cancer Letters, 2024 - Elsevier
Abstract Anti-CDK4/6 therapy has been employed for the treatment for head and neck
squamous cell carcinoma (HNSCC) with CDK4/6 hyperactivation, but the response rate is …
squamous cell carcinoma (HNSCC) with CDK4/6 hyperactivation, but the response rate is …
Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity
C Lian, C Zhang, P Tian, Q Tan, Y Wei… - … and Targeted Therapy, 2024 - nature.com
Epigenetic readers frequently affect gene regulation, correlate with disease prognosis, and
hold significant potential as therapeutic targets for cancer. Zinc finger MYND-type containing …
hold significant potential as therapeutic targets for cancer. Zinc finger MYND-type containing …
[HTML][HTML] Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer
S Yu, Y Si, M Xu, Y Wang, C Liu, C Bi, M Sun… - Journal of Biological …, 2024 - Elsevier
The combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy is the first-line
therapy for ER+/Her2-breast cancer, however, the development of drug resistance limited …
therapy for ER+/Her2-breast cancer, however, the development of drug resistance limited …
[HTML][HTML] Role of PRMT1 and PRMT5 in Breast Cancer
S Martinez, S Sentis, C Poulard, O Trédan… - International Journal of …, 2024 - mdpi.com
Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage
breast cancer is curable in~ 70–80% of patients, while advanced metastatic breast cancer is …
breast cancer is curable in~ 70–80% of patients, while advanced metastatic breast cancer is …
[HTML][HTML] Long-Read MDM4 Sequencing Reveals Aberrant Isoform Landscape in Metastatic Melanomas
N Patrick, M Markey - International Journal of Molecular Sciences, 2024 - mdpi.com
MDM4 is upregulated in the majority of melanoma cases and has been described as a “key
therapeutic target in cutaneous melanoma”. Numerous isoforms of MDM4 exist, with few …
therapeutic target in cutaneous melanoma”. Numerous isoforms of MDM4 exist, with few …
[HTML][HTML] A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer
Y Wang, D Chu, H Li, J Fan, X Zhu, Y Ma… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
The increasing incidence and mortality associated with lung cancer (LC) is a significant
global health challenge. The underlying mechanisms contributing to LC remain …
global health challenge. The underlying mechanisms contributing to LC remain …
Productive mRNA Chromatin Escape is Promoted by PRMT5 Methylation of SNRPB
JD DeAngelo, MI Maron, JS Roth, AM Silverstein… - …, 2024 - pmc.ncbi.nlm.nih.gov
Protein Arginine Methyltransferase 5 (PRMT5) regulates RNA splicing and transcription by
symmetric dimethylation of arginine residues (Rme2s/SDMA) in many RNA binding proteins …
symmetric dimethylation of arginine residues (Rme2s/SDMA) in many RNA binding proteins …